OBJECTIVES: To compare the effectiveness of adalimumab monotherapy and adalimumab and methotrexate (MTX) combination therapy in patients with established rheumatoid arthritis. METHODS: Data from an ongoing longitudinal observational study in Norway were used to compare response to treatment with two different adalimumab regimens (monotherapy, n = 84; combination with MTX, n = 99). Patients were assessed with measures of disease activity, health status and utility scores. Within-group changes were analysed from baseline to follow-up at 3 and 6 months and the changes were compared between groups after adjustment for the propensity score. The groups were also compared for the proportions of patients achieving European League Against Rheumatism (EULAR) good response, Disease Activity Score (DAS)28 remission and treatment terminations. RESULTS: The improvement from baseline was significant for all measures in the adalimumab and MTX group, but only for DAS28, joint counts, two Short-form Health Survey with 36 questions (SF-36) dimensions and patient's and investigator's global assessment in the monotherapy group. All between-group differences were numerically in favour of combination therapy and significant for C reactive protein, joint counts, DAS28, Modified Health Assessment Questionnaire, investigator's global assessment, four SF-36 dimensions and Short Form 6D at 6 months. More patients in the combination therapy group reached EULAR good response (p<0.001) and remission (p = 0.07). At 6 months, 80.8% of the patients in the combination therapy group and 59.5% in the monotherapy group remained on treatment (p = 0.002). More withdrawals in the monotherapy group were due to adverse events. CONCLUSIONS: Our results were consistent across several categories of end points and suggest that adalimumab combined with MTX is effective in patients with rheumatoid arthritis treated in daily clinical practice and is superior to adalimumab monotherapy.
OBJECTIVES: To compare the effectiveness of adalimumab monotherapy and adalimumab and methotrexate (MTX) combination therapy in patients with established rheumatoid arthritis. METHODS: Data from an ongoing longitudinal observational study in Norway were used to compare response to treatment with two different adalimumab regimens (monotherapy, n = 84; combination with MTX, n = 99). Patients were assessed with measures of disease activity, health status and utility scores. Within-group changes were analysed from baseline to follow-up at 3 and 6 months and the changes were compared between groups after adjustment for the propensity score. The groups were also compared for the proportions of patients achieving European League Against Rheumatism (EULAR) good response, Disease Activity Score (DAS)28 remission and treatment terminations. RESULTS: The improvement from baseline was significant for all measures in the adalimumab and MTX group, but only for DAS28, joint counts, two Short-form Health Survey with 36 questions (SF-36) dimensions and patient's and investigator's global assessment in the monotherapy group. All between-group differences were numerically in favour of combination therapy and significant for C reactive protein, joint counts, DAS28, Modified Health Assessment Questionnaire, investigator's global assessment, four SF-36 dimensions and Short Form 6D at 6 months. More patients in the combination therapy group reached EULAR good response (p<0.001) and remission (p = 0.07). At 6 months, 80.8% of the patients in the combination therapy group and 59.5% in the monotherapy group remained on treatment (p = 0.002). More withdrawals in the monotherapy group were due to adverse events. CONCLUSIONS: Our results were consistent across several categories of end points and suggest that adalimumab combined with MTX is effective in patients with rheumatoid arthritis treated in daily clinical practice and is superior to adalimumab monotherapy.
Authors: Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash Journal: Arthritis Rheum Date: 2003-01
Authors: Ronald F van Vollenhoven; Sofia Ernestam; Anders Harju; Johan Bratt; Lars Klareskog Journal: Arthritis Res Ther Date: 2003-10-01 Impact factor: 5.156
Authors: Jeffrey D Greenberg; Mitsumasa Kishimoto; Vibeke Strand; Stanley B Cohen; Thomas P Olenginski; Thomas Harrington; Shelly P Kafka; George Reed; Joel M Kremer Journal: Am J Med Date: 2008-06 Impact factor: 4.965
Authors: Sandeep K Agarwal; Roberta J Glass; Nancy A Shadick; Jonathan S Coblyn; Ronald J Anderson; Nancy E Maher; Michael E Weinblatt; Daniel H Solomon Journal: J Rheumatol Date: 2008-07-15 Impact factor: 4.666
Authors: Kathleen M Gillooly; Claudine Pulicicchio; Mark A Pattoli; Lihong Cheng; Stacey Skala; Elizabeth M Heimrich; Kim W McIntyre; Tracy L Taylor; Daniel W Kukral; Shailesh Dudhgaonkar; Jignesh Nagar; Dana Banas; Scott H Watterson; Joseph A Tino; Aberra Fura; James R Burke Journal: PLoS One Date: 2017-07-24 Impact factor: 3.240
Authors: Charlotte Louise Maria Krieckaert; Geertje Margret Bartelds; Willem Frederik Lems; Gerrit Jan Wolbink Journal: Arthritis Res Ther Date: 2010-10-20 Impact factor: 5.156
Authors: Vibeke Strand; Philip Mease; Gerd R Burmester; Enkeleida Nikaï; Geoffroy Coteur; Ronald van Vollenhoven; Bernard Combe; Edward C Keystone; Arthur Kavanaugh Journal: Arthritis Res Ther Date: 2009-11-12 Impact factor: 5.156
Authors: Dao X Nguyen; Alice Cotton; Laura Attipoe; Coziana Ciurtin; Caroline J Doré; Michael R Ehrenstein Journal: J Allergy Clin Immunol Date: 2018-06-20 Impact factor: 10.793